ACTEMRA® (tocilizumab)
ALECENSA® (alectinib)
Avastin® (bevacizumab)
COLUMVI® (glofitamab-gxbm)
COTELLIC® (cobimetinib)
ENSPRYNG™ (satralizumab-mwge)
Erivedge® (vismodegib)
Evrysdi® (risdiplam)
GAZYVA® (obinutuzumab)
HEMLIBRA® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
Itovebi™ (inavolisib)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO® (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq)
PERJETA® (pertuzumab)
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
PiaSky™ (crovalimab-akkz)
POLIVY® (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa) Inhalation Solution
Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
RITUXAN® (rituximab) for Oncology
Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK® (entrectinib)
SUSVIMO® (ranibizumab injection)
TECENTRIQ® (atezolizumab)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
VABYSMO® (faricimab-svoa)
VENCLEXTA® (venetoclax tablets)
XOLAIR® (omalizumab) for subcutaneous use
ZELBORAF® (vemurafenib)
Oncology
Ophthalmology
Rheumatology
To contact MySMA Support call (833) 387-9734 (9 a.m.–8 p.m. ET, Monday through Friday).
Quickly Enroll in MySMA Support brochure
The Quickly Enroll in MySMA Support brochure provides a step-by-step overview of using eSubmit (also known as Quick Enroll) to enroll patients in MySMA Support.
Enrolling Patients in MySMA Support by Genentech brochure
The Enrolling Patients in MySMA Support brochure provides tips for completing the Evrysdi Start Form and includes important information about the MySMA Support team.
MySMA Support for Evrysdi Enrollment Forms
The Evrysdi Start Form includes the Patient Consent Form (page 4), which is to be completed by the patient, and the Prescriber Service Form (page 6), which is to be completed by the health care provider. Both pages must be completed for enrollment. To use Quick Enroll for the Evrysdi Start Form, select eSubmit.
-
Evrysdi Start Form
The Evrysdi Start Form is used to enroll people who have been prescribed Evrysdi into MySMA Support.
The provider section is used to collect the patient’s health insurance and treatment information.
The patient section gives permission for Genentech to work with the health care provider and the patient’s health insurance plan. -
Patient consent section of the Evrysdi Start Form
Electronically submit or download the patient section of the Evrysdi Start Form. -
Spanish form: Formulario de Inicio de Evrysdi
Electronically submit or download the Spanish version of the patient section of the Evrysdi Start Form.
-
Complete and submit a form electronically.
Other Important Documents
A Road Map for Helping Patients: How MySMA Support Can Help You and Your Patients
This guide provides an overview of how MySMA Support may help patients who have been prescribed Evrysdi access their medicine as well as tips on navigating health insurance coverage and appeals processes.
Considerations for Composing a Letter of Medical Necessity
This guide provides tips to help you draft a letter of medical necessity. A sample letter is also included for your reference. Use the links below to find additional information to enclose in your letter.
FDA approval letter (Follow this link and search by the drug name)
Considerations for Composing a Sample Appeal Letter
This guide provides tips to help you draft an appeal letter. A sample letter is also included for your reference. Use the links below to find additional information to enclose in your letter.
FDA approval letter (Follow this link and search by the drug name)
For assistance, call (877) GENENTECH/(877) 436-3683
6 a.m.–5 p.m. PT, Monday through Friday
To enroll in MySMA Support, complete and submit the Evrysdi Start Form